Taiwan's Pharma Market to Reach $8.4 Billion by 2020
July 15, 2015.
Taiwan’s pharmaceutical market will expand in value from $5.4 billion in 2013 to approximately $8.4 billion by 2020, according to a GlobalData report. This is despite the ongoing political tensions with China.
The report states that diplomatic isolation, high out-of-pocket expenditure and the inefficient distribution of healthcare facilities are the foremost challenges to Taiwan’s pharmaceutical sector. With many people in Taiwan also fearing a move towards reunification with China, the outcome of the 2016 general election will be key.
However, according to GlobalData's Joshua Owide, Taiwan’s pharmaceutical outlook remains positive, with opportunities presented by a free trade agreement with the US, low-taxation investment environment, harmonized clinical trial process, an efficient patent system, and strong incentives for R&D.
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Republic of China (Taiwan)
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
